Prevalence of optimal treatment regimens in patients with apparent treatment-resistant hypertension based on office blood pressure in a community-based practice network. - Wikidata - awgldk - TriplyDB

Prevalence of optimal treatment regimens in patients with apparent treatment-resistant hypertension based on office blood pressure in a community-based practice network.

Prevalence of optimal treatment regimens in patients with apparent treatment-resistant hypertension based on office blood pressure in a community-based practice network.

http://www.wikidata.org/entity/Q33789175

about

Treatment Resistant Hypertension Mineralocorticoid Receptor Antagonists Therapy in Resistant Hypertension: Time to Implement Guidelines!Refractory and Resistant Hypertension: Antihypertensive Treatment Failure versus Treatment Resistance Kidney Function Decline and Apparent Treatment-Resistant Hypertension in the Elderly A comprehensive review of an unmet public health issue: resistant hypertension.African Americans, hypertension and the renin angiotensin system Management of Resistant Hypertension: Do Not Give Up on Medication.Evaluating factors associated with uncontrolled hypertension: Isfahan cohort study, Iran.Systematic review and meta-analysis of the prevalence of resistant hypertension in treated hypertensive populations.Differential phenotypes of tissue-infiltrating T cells during angiotensin II-induced hypertension in mice.Prevalence of resistant hypertension and associated factors for blood pressure control status with optimal medical therapy using Korean ambulatory blood pressure monitoring registry data.Prevalence of pseudoresistant hypertension due to inaccurate blood pressure measurement.Resistant or refractory hypertension: are they different?Managing Treatment-Resistant Patients.Quality of Life in Treatment-Resistant Hypertension.Carotid baroreflex activation therapy for resistant hypertension.Management of resistant hypertension: expert consensus statement from the French Society of Hypertension, an affiliate of the French Society of Cardiology.Drug Development for Hypertension: Do We Need Another Antihypertensive Agent for Resistant Hypertension?No Time to Waste: in Support of Aggressive and Immediate Management of Hypertension.Recognition and Management of Resistant Hypertension.Should All Patients with Resistant Hypertension Receive Spironolactone?Renal sympathetic denervation for treatment of resistant hypertension: Egyptian experience.Multidisciplinary Approach in the Treatment of Resistant Hypertension.Resistant Hypertension: An Update of Experimental and Clinical Findings.White-Coat Effect Is Uncommon in Patients With Refractory Hypertension.Impact of Implementing the 2013 ACC/AHA Cholesterol Guidelines on Vascular Events in a Statewide Community-Based Practice Registry.Improvement in All-Cause Mortality With Blood Pressure Control in a Group of US Veterans With Drug-Resistant Hypertension.Aldosterone Antagonists or Renin-Guided Therapy for Treatment-Resistant Hypertension: A Comparative Effectiveness Pilot Study in Primary Care.7th Brazilian Guideline of Arterial Hypertension: Chapter 13 - Resistant Arterial Hypertension The quality of quality: is it time for new tools?Refractory versus resistant hypertension: Novel distinctive phenotypes.Response to Comment on optimal treatment for resistant hypertension: the missing data on pulse wave velocity.Hypertension control: population surveys vs clinical studies.Resistant hypertension: risk factors, subclinical atherosclerosis, and comorbidities among adults-the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil).Resistant hypertension: a therapeutic challenge.[Resistant hypertension : What is it?].Prevalence of treatment-resistant hypertension after considering pseudo-resistance and morbidity: a cross-sectional study in Irish primary care.American Society of Hypertension Scientific Statements Addressing Resistant Hypertension.Characteristics and treatment of African-American and European-American patients with resistant hypertension identified using the electronic health record in an academic health centre: a case-control study.Advances in resistant hypertension

P2860

Q26775459-C44DEBDC-9B45-4C6B-AA7E-C2D6FD5C5465 Q26776149-E2EB141D-9274-42CF-95C3-675F5340DDB7 Q28078151-1280FBF4-08ED-4BBC-A699-A85FD6131AF6 Q28552819-07E793B0-8794-4521-91DE-6D06D5016012 Q30235310-C159A76D-108E-487C-A00D-838EFDD675B7 Q34251854-D49B5DBA-D523-4ACC-A57E-88773A2EBC41 Q35026633-814C240A-EDF3-494B-A06C-362721B69D4B Q35160615-BB3B120F-EFCB-49C2-8970-FC9DB52C9928 Q35231679-E204A1F1-E3A6-477A-9D7D-4718207601A1 Q35514655-5ED8A2DC-6998-4CDF-A89D-305DDE3FB808 Q35928187-58582CA3-ED78-49A0-B207-8E7402A03D62 Q36999231-E15FAFCA-9FB8-402D-AC54-1877ACF028CA Q38241508-FF4510E1-AFB9-40C5-B997-B64D9B691B9E Q38508113-260DE5F9-E7A1-4CD4-92C3-05BC73D7882E Q38538689-C052B567-A34D-4AD4-A793-E8E79483F2D6 Q38543355-C223E78A-5C0A-4DA5-B9D7-E9F2A32D29F1 Q38714429-29F0DF6C-C14A-4BB8-A5CA-19D49812DFDF Q38763352-7ACE5B7E-F559-4740-BFC0-7151D36CBF8D Q38763355-8B9F47A5-4AF7-450B-9380-F057F75A510A Q38789707-4FE35FB5-589C-4D47-A0D7-328CE509B281 Q38992649-8476D9FB-71B1-43D6-89E4-CB8FDEB146D5 Q39043832-26CFF76F-C1C4-4432-A522-3F09A8C0E96E Q39129288-58AA6186-1186-4B87-BE20-EBBC78755751 Q39308306-D9A68FCE-D012-48F2-A7EC-7C57374B2378 Q40127668-E391A4C7-D48B-4C49-9C1A-DFB3B9043ABC Q40275485-31ACABA4-7768-4C5D-8F22-DF99F8210ABB Q40461830-9583B7E3-C3C3-4A81-BE3E-AFA13D00AD42 Q42231371-6E20F7F1-0FDA-487C-9922-21135A35BDD0 Q42320532-17E4C923-0ADB-49AE-B508-E5ABFA6C4662 Q42338673-E7854B27-D585-4DC9-8EDC-14A05ED1FB6A Q42376948-C32D50C8-0C0E-42AA-AA43-772EE339EDA4 Q42381223-16820211-1DB5-45B4-B4D0-76813422281F Q43522402-1FD17665-9ED0-45C0-9D3F-21541339FCC0 Q44847576-952229DE-7232-41B7-A78E-CEB14B5896C0 Q48279650-E659D04C-A2BD-4873-AB39-12E747AD871F Q52869825-72F452AF-1197-4D53-BCE3-CA1D8B7CE783 Q53685805-A1B177D8-6C0D-458C-9F41-AF0DE8B0680D Q53832250-8664503F-5DCE-425D-99E7-43063B9A6C7B Q55396649-7B04A226-B49F-4E24-8B2A-EFF453CDC1E3 Q58804818-2D4E6B96-ACA4-463E-BDE4-695AE5E87767

P2860

Prevalence of optimal treatment regimens in patients with apparent treatment-resistant hypertension based on office blood pressure in a community-based practice network.

http://www.wikidata.org/entity/Q33789175

description

2013 nî lūn-bûn

@nan

2013 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

name

Prevalence of optimal treatmen ...... munity-based practice network.

@ast

Prevalence of optimal treatmen ...... munity-based practice network.

@en

type

label

Prevalence of optimal treatmen ...... munity-based practice network.

@ast

Prevalence of optimal treatmen ...... munity-based practice network.

@en

prefLabel

Prevalence of optimal treatmen ...... munity-based practice network.

@ast

Prevalence of optimal treatmen ...... munity-based practice network.

@en

P1433

Q33789175-FABE0D6E-E826-4C06-841B-1482C0E94C22

P1476

Q33789175-68107185-D125-414A-A592-67CB54FD9814

P2093

Q33789175-144F20A1-46DB-4CBF-928D-D4B005DA30F1

Q33789175-17BC7109-6106-4AA7-ACD0-EF66FEA60943

Q33789175-195FC7E9-2308-4CA1-852E-AB91412F52E4

Q33789175-84D23E5A-4CBE-4EB5-A54A-E8D73C357F07

Q33789175-B6DBF077-A775-4118-8D78-3BBBAC5C4EE4

Q33789175-B9D25809-DA66-4A37-878F-AD89CE80F29F

Q33789175-CE92DE4C-CF0A-40A2-8FE5-7BBABC58030A

P2860

Q33789175-05229E6B-2F47-477E-8792-545381DE113E

Q33789175-0BE1BE23-40DB-4555-B320-E454E410A79F

Q33789175-0C1800B8-816E-4AB0-BD7F-EA21B37459C6

Q33789175-208C9AD1-6425-403F-9D48-5D3E92D4C2C0

Q33789175-2CB98490-8307-4DA4-97BD-A94BBAD67668

Q33789175-2CF68EF5-2A7E-41FD-958E-F4C2EBBB3051

Q33789175-37692757-2A08-40CB-9803-218ED75AE959

Q33789175-38981008-C557-4DBB-8E66-B41F47DDB631

Q33789175-581C5E6E-FBCA-4FDF-9E9E-A34BE9BA5622

Q33789175-58540D19-56F9-4EA6-A192-56EDDA90AF64

P304

Q33789175-B469702C-1D8F-40EA-9C7B-FBABE9D071AF

P31

Q33789175-6EBBAF1B-EF58-4E54-A87D-BBA80280EF0D

P356

Q33789175-40BDE7CF-5F72-4ED1-AA7B-3800D05BDB2F

P407

Q33789175-D60D6007-D6BC-457E-B7FB-C59EF8DE30AD

P433

Q33789175-CB2D51EA-C433-488C-AA4C-763EB2FB5C14

P478

Q33789175-11459B6A-C4BE-4F1F-9D5A-35A927A9E28D

P577

Q33789175-9C75446E-0692-4C75-AD04-AEB85D92076B

P698

Q33789175-D783FBCD-9C00-4439-99E9-2B1099AA8207

P921

Q33789175-0CC689AC-1B22-4032-9C14-26ED998EBE35

P932

Q33789175-4CD77B28-A6BC-4590-AB25-555953236223

P356

HYPERTENSIONAHA.113.01448

P1433

P1476

Prevalence of optimal treatmen ...... munity-based practice network.

@en

P2093

Brent M Egan

http://www.w3.org/2001/XMLSchema#string

David A Calhoun

http://www.w3.org/2001/XMLSchema#string

Jiexiang Li

http://www.w3.org/2001/XMLSchema#string

Robert D Brook

http://www.w3.org/2001/XMLSchema#string

Thomas M Todoran

http://www.w3.org/2001/XMLSchema#string

W Adam Brzezinski

http://www.w3.org/2001/XMLSchema#string

Yumin Zhao

http://www.w3.org/2001/XMLSchema#string

P2860

Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure

Effects of intensive blood-pressure control in type 2 diabetes mellitus.

Progression is accelerated from prehypertension to hypertension in blacks

Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate.

Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research.

Uncontrolled and apparent treatment resistant hypertension in the United States, 1988 to 2008

Pharmacogenomics of blood pressure response to antihypertensive treatment.

Initial monotherapy and combination therapy and hypertension control the first year

Prevalence and correlates of low medication adherence in apparent treatment-resistant hypertension.

Different definitions of prevalent hypertension impact: the clinical epidemiology of hypertension and attainment of Healthy People goals.

P304

691-697

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1161/HYPERTENSIONAHA.113.01448

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

62

http://www.w3.org/2001/XMLSchema#string

P577

2013-08-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23918752

http://www.w3.org/2001/XMLSchema#string

P921

arterial hypertension

P932

4066303

http://www.w3.org/2001/XMLSchema#string